Nectar Lifescience Ltd's Q3FY25 Quarter Results
- 1d ago
Result Summary
- Nectar Lifescience Ltd reported a 6.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.6%.
- Its expenses for the quarter were up by 5.4% QoQ and down 1.6% YoY.
- The net profit increased 40.0% QoQ and increased 399.4% YoY.
- The earnings per share (EPS) of Nectar Lifescience Ltd stood at 0.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 455.56 | 428.79 | 452.65 | 6.2% | 0.6% |
Total Expenses | 443.00 | 420.12 | 450.19 | 5.4% | -1.6% |
Profit Before Tax | 12.55 | 8.67 | 2.46 | 44.8% | 410.2% |
Tax | 4.71 | 3.07 | 0.89 | 53.4% | 429.2% |
Profit After Tax | 7.84 | 5.60 | 1.57 | 40.0% | 399.4% |
Earnings Per Share | 0.30 | 0.30 | 0.10 | 0.0% | 200.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nectar Lifescience Ltd is a leading company operating in the pharmaceutical industry. The company primarily focuses on manufacturing and supplying a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, and phytochemicals. Nectar Lifescience is known for its strong commitment to quality and innovation, serving both domestic and international markets. Recent major developments for the company are not available in the provided data, so any specific advancements or strategic changes cannot be commented upon.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Nectar Lifescience Ltd reported a total income of ₹455.56 crores. This represents a quarter-over-quarter (QoQ) increase of 6.2% compared to Q2FY25, where the total income was ₹428.79 crores. On a year-over-year (YoY) basis, the total income saw a modest increase of 0.6% from Q3FY24, which recorded ₹452.65 crores. The revenue growth in this quarter indicates a stable performance over the previous year and a significant improvement over the last quarter.
Profitability
The profitability of Nectar Lifescience Ltd shows a positive trajectory in Q3FY25, with a Profit Before Tax (PBT) of ₹12.55 crores, which marks a substantial QoQ growth of 44.8% from ₹8.67 crores in Q2FY25. The YoY comparison reveals an even more dramatic increase of 410.2% from ₹2.46 crores in Q3FY24. The Profit After Tax (PAT) also improved significantly, standing at ₹7.84 crores in Q3FY25, a 40.0% increase from Q2FY25’s ₹5.60 crores and a remarkable 399.4% rise from ₹1.57 crores in Q3FY24. The Earnings Per Share (EPS) remained constant at ₹0.30 in Q3FY25 compared to the previous quarter but showed a 200.0% increase from ₹0.10 in Q3FY24.
Operating Metrics
Examining the operating metrics, the total expenses for Q3FY25 were ₹443.00 crores, representing a QoQ increase of 5.4% from ₹420.12 crores in Q2FY25. However, there is a slight YoY decrease of 1.6% from ₹450.19 crores in Q3FY24. The company's tax expense for Q3FY25 was ₹4.71 crores, reflecting a QoQ increase of 53.4% from ₹3.07 crores in Q2FY25 and a YoY rise of 429.2% from ₹0.89 crores in Q3FY24. These figures highlight significant enhancements in the company's operating efficiency and profitability over both the quarter and the year. The data does not provide information regarding other operating metrics such as the P/E ratio, debt-to-equity ratio, or current ratio, thus they are not included in this analysis.
